Moderna
Impact of New CDC Guidelines on RSV Vaccine Makers
RSV vaccine, CDC guidelines, vaccine makers, Moderna, Pfizer, GSK, Guillain-Barré syndrome, vaccination recommendations
Flagship’s Noubar Afeyan on Uncertainty, AI, and the Future of Biotechnology
, Noubar Afeyan, Flagship Pioneering, Biotechnology, Artificial Intelligence (AI), Uncertainty, Innovation, Future of Biotech, Moderna, Venture Capital,
Moderna Secures $176 Million BARDA Award for Bird Flu Vaccine Development
Moderna, BARDA, Bird Flu, Vaccine Development, mRNA Technology, Pandemic Preparedness
Moderna’s Combination Flu and COVID-19 Vaccine Shows Promising Results in Late-Stage Trial
Moderna, flu vaccine, COVID-19 vaccine, combination vaccine, mRNA-1083, late-stage trial, immune response, influenza, SARS-CoV-2, respiratory viruses
Moderna and Merck’s Cancer Vaccine Shows Promising Results in Combination with Keytruda
Moderna, Merck, Cancer Vaccine, Keytruda, Melanoma, mRNA Technology, ASCO, FDA, Rare Disease, START Pilot Program
FDA Approves Moderna’s RSV Vaccine, Marking Its Second Commercial Product
Moderna, RSV Vaccine, FDA Approval, mRNA Technology, Respiratory Syncytial Virus, COVID-19, Spikevax, mRESVIA
Moderna Secures Victory in EU Patent Dispute with Pfizer-BioNTech over COVID-19 Vaccine
Moderna, Pfizer, BioNTech, EU, patent dispute, COVID-19 vaccine, mRNA technology, European Patent Office (EPO), intellectual property rights, pharmaceutical industry.
Moderna’s Diversification Strategy Hindered by FDA Delay in RSV Vaccine Review
Moderna, FDA, RSV vaccine, diversification strategy, vaccine review, delay
Moderna’s RSV Vaccine Decision Postponed by FDA to Late May
FDA, Moderna, RSV vaccine, decision, delay, May
Moderna Terminates Gene Editing Partnership, Shifts Focus to mRNA Technology
Moderna, Metagenomi, gene editing, partnership, mRNA technology, biotechnology, biobucks, deal termination